WASHINGTON, DC--(Marketwire - March 24, 2008) - Kinexum Metabolics, Inc. (KMI) announced Peter Damsbo, M.D. has joined the clinical development team that is designing human trials for INGAP Peptide which are scheduled to begin in 2008. Dr. Damsbo was formerly Vice President, Clinical Drug Development for diabetes and growth hormones at Novo Nordisk. He joins a distinguished team of advisors and diabetes experts to advance the development of INGAP Peptide for the treatment of Type 1 diabetes and insulin-dependent Type 2 diabetes patients.
